α1-Adrenergic Receptors and Their Inhibitors in Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia

No abstract is available for this paper.

• Publication year

  2004

• Venue

  The Journal of Urology

• Publication date

  2004-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/01.JU.0000097026.43866.CC
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels

  2003cited by this paper
• Safety and efficacy of alfuzosin 10 mg once‐daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double‐blind, placebo‐controlled studies

  2003cited by this paper
• Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: a retrospective analysis.

  2003cited by this paper
• Doxazosin and congestive heart failure.

  2002cited by this paper
• Are all α-blockers created equal? An update

  2002cited by this paper
• Modulation of bladder α1-adrenergic receptor subtype expression by bladder outlet obstruction

  2002cited by this paper
• Symptomatic and asymptomatic benign prostatic hyperplasia: Molecular differentiation by using microarrays

  2002cited by this paper
• α-Adrenoceptors and benign prostatic hyperplasia: basic principles for treatment with α-adrenoceptor antagonists

  2002cited by this paper
• Congenital Obstruction of the Posterior Urethra1

  2002cited by this paper
• α-Adrenoceptor Antagonists in the Treatment of Benign Prostate Hyperplasia

  2002cited by this paper
• A combined analysis of double‐blind trials of the efficacy and tolerability of doxazosin‐gastrointestinal therapeutic system, doxazosin standard and placebo in patients with benign prostatic hyperplasia

  2001cited by this paper
• Alfuzosin: overview of pharmacokinetics, safety, and efficacy of a clinically uroselective α-blocker

  2001cited by this paper
• In vitro and in vivo uroselectivity of B8805-033, an antagonist with high affinity at prostatic α1A- vs. α1B- and α1D-adrenoceptors

  2001cited by this paper
• The role of α1‐adrenergic receptor subtypesin lower urinary tract symptoms

  2001cited by this paper
• Alpha-adrenoceptor subtypes.

  2001cited by this paper
• Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo-controlled trial.

  2001cited by this paper
• Terazosin, doxazosin, and prazosin: current clinical experience.

  2001cited by this paper
• Worldwide experience with alfuzosin and tamsulosin.

  2001cited by this paper
• Long-term, open-label, phase III multicenter study of tamsulosin in benign prostatic hyperplasia.

  2001cited by this paper
• α1‐Adrenergic receptors in the lower urinary tract and vascular bed: potential role for the α1d subtype in filling symptoms and effects of ageing on vascular expression

  2000cited by this paper
• Novel role for α1‐adrenergic receptor subtypes in lower urinary tract symptoms

  2000cited by this paper
• Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)

  2000cited by this paper
• [Pharmacological properties of naftopidil, a drug for treatment of the bladder outlet obstruction for patients with benign prostatic hyperplasia].

  2000cited by this paper
• The mechanism of adverse events associated with terazosin: an analysis of the Veterans Affairs cooperative study.

  2000cited by this paper
• Alpha blockers: are all created equal?

  2000cited by this paper
• An Investigation of the Uroselective Properties of Four Novel α1a-Adrenergic Receptor Subtype-Selective Antagonists

  2000cited by this paper
• Smooth muscle and parasympathetic nerve terminals in the rat urinary bladder have different subtypes of α1 adrenoceptors

  2000cited by this paper
• Efficacy and Safety of a New Prolonged Release Formulation of Alfuzosin 10 mg Once Daily versus Alfuzosin 2.5 mg Thrice Daily and Placebo in Patients with Symptomatic Benign Prostatic Hyperplasia

  2000cited by this paper
• Medical Therapy for Benign Prostatic Hyperplasia: A Review of the Literature

  2000cited by this paper
• Clinical Pharmacology of α1-Adrenoceptor Antagonists

  1999cited by this paper
• Benign prostatic hyperplasia (the aging prostate).

  1999cited by this paper
• A Meta-Analysis on the Efficacy and Tolerability of α1-Adrenoceptor Antagonists in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Obstruction

  1999cited by this paper
• History and Nomenclature of α1-Adrenoceptors

  1999cited by this paper
• Asymptomatic inflammation and/or infection in benign prostatic hyperplasia

  1999cited by this paper
• Clinical pharmacology of alpha1-adrenoceptor antagonists.

  1999cited by this paper
• Localization and expression of the alpha1A-1, alpha1B and alpha1D-adrenoceptors in hyperplastic and non-hyperplastic human prostate.

  1999cited by this paper
• Subtype Specific Regulation of Human Vascular α1-Adrenergic Receptors by Vessel Bed and Age

  1999cited by this paper
• Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group.

  1999cited by this paper
• A Double-Blind Comparison of Terazosin and Tamsulosin on Their Differential Effects on Ambulatory Blood Pressure and Nocturnal Orthostatic Stress Testing

  1998cited by this paper
• In vivo receptor binding of novel alpha1-adrenoceptor antagonists for treatment of benign prostatic hyperplasia.

  1998cited by this paper
• A second phase III multicenter placebo controlled study of 2 dosages of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasia. United States 93-01 Study Group.

  1998cited by this paper
• Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group.

  1998cited by this paper
• Alpha1-adrenergic receptor subtypes in human detrusor.

  1998cited by this paper
• Relationship between the effects of alfuzosin on rat urethral and blood pressures and its tissue concentrations.

  1998cited by this paper
• Long-Term Evaluation of Tamsulosin in Benign Prostatic Hyperplasia: Placebo-Controlled, Double-Blind Extension of Phase III Trial

  1998cited by this paper
• The effects of tamsulosin, a high affinity antagonist at functional α1A‐ and α1D‐adrenoceptor subtypes

  1997cited by this paper
• A dose‐ranging study of the efficacy and safety of tamsulosin, the first prostate‐selective a1A‐adrenoceptor antagonist*, in patients with benign prostatic obstruction

  1997cited by this paper
• Quantification and distribution of α1‐adrenoceptor subtype mRNAs in human prostate: comparison of benign hypertrophied tissue and non‐hypertrophied tissue

  1996cited by this paper
• Tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist. A meta-analysis of two randomized, placebo-controlled, multicentre studies in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study Group.

  1996cited by this paper
• The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group.

  1996cited by this paper
• The Hytrin Community Assessment Trial study: a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. HYCAT Investigator Group.

  1996cited by this paper
• Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies.

  1996cited by this paper
• α1-Adrenergic receptors in human spinal cord: specific localized expression of mRNA encoding α1-adrenergic receptor subtypes at four distinct levels

  1995cited by this paper
• Localization of the alpha 1A-adrenoceptor in the human prostate.

  1995cited by this paper
• Pathophysiology of clinical benign prostatic hyperplasia.

  1995cited by this paper
• Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: a double-blind, placebo-controlled, dose-response multicenter study.

  1995cited by this paper
• International Union of Pharmacology. X. Recommendation for nomenclature of alpha 1-adrenoceptors: consensus update.

  1995cited by this paper
• Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels.

  1995cited by this paper
• Tamsulosin, a selective α1c‐adrenoceptor* antagonist: a randomized, controlled trial in patients with benign prostatic ‘obstruction’ (symptomatic BPH)

  1995cited by this paper
• Doxazosin in the Treatment of Benign Prostatic Hyperplasia in Normotensive Patients: A Multicenter Study *

  1995cited by this paper
• Doxazosin Update of its Clinical Pharmacology and Therapeutic Applications in Hypertension and Benign Prostatic Hyperplasia

  1995cited by this paper
• Localization of mRNA for three distinct alpha 1-adrenergic receptor subtypes in human tissues: implications for human alpha-adrenergic physiology.

  1994cited by this paper
• Effect of naftopidil on urethral obstruction in benign prostatic hyperplasia: Assessment by urodynamic studies

  1994cited by this paper
• Pathophysiology of benign prostatic hyperplasia.

  1994cited by this paper
• The effect of terazosin on bladder function in the spinal cord injured patient.

  1994cited by this paper
• The alpha‐adrenoceptor subtype mediating the tension of human prostatic smooth muscle

  1993cited by this paper
• Identification, quantification, and localization of mRNA for three distinct alpha 1 adrenergic receptor subtypes in human prostate.

  1993cited by this paper
• A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia.

  1992cited by this paper
• Use of terazosin in the medical treatment of benign prostatic hyperplasia: experience in Italy.

  1992cited by this paper
• Alpha-adrenergic blockers for the treatment of benign prostatic hyperplasia.

  1990cited by this paper
• The development of human benign prostatic hyperplasia with age.

  1984cited by this paper
• Hormone blood levels and their inter-relationships in normal men and men with benign prostatic hyperplasia (BPH).

  1979cited by this paper
• The use of alpha-adrenergic blockers in benign prostatic obstruction.

  1976cited by this paper
• Presynaptic regulation of catecholamine release.

  1974cited by this paper
• Familial incomplete male pseudohermaphroditism, type 2. Decreased dihydrotestosterone formation in pseudovaginal perineoscrotal hypospadias.

  1974cited by this paper
• A study of the adrenotropic receptors.

  1948cited by this paper

• Beyond the Prostate: A Visionary Study on Ocular Impacts of Benign Prostatic Hyperplasia Drugs

  2025cites this paper
• CYP2D6 genetic polymorphisms impact on tamsulosin efficacy and safety in patients with benign prostatic hyperplasia

  2025cites this paper
• Intraoperative floppy iris syndrome: Our experience

  2025cites this paper
• A Systematic Review and Meta-Analysis of Doxazosin Pharmacokinetics in Healthy and Diseased Populations

  2025cites this paper
• Molecular mechanism of human α1A-adrenoceptor inhibition by Mamba snake toxin AdTx1

  2025cites this paper
• Medical Therapy for Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms.

  2025cites this paper
• A Novel ADRA1A Missence Variant (c.939G > T) in Two Related Patients with Anejaculation: Case Report

  2024cites this paper
• Capsaicin reduces blood glucose and prevents prostate growth by regulating androgen, RAGE/IGF-1/Akt, TGF-β/Smad signalling pathway and reversing epithelial-mesenchymal transition in streptozotocin-induced diabetic mice

  2024cites this paper
• Serum levels of prostate specific antigen, free PSA, [−2]proPSA, fPSA/tPSA ratio, Prostate Health Index, and glycosylation patterns of free PSA in patients with benign prostatic hyperplasia pharmacotherapy

  2024cites this paper
• MEDICAL EXPULSIVE THERAPY FOR UROLITHIASIS IN CHILDREN: EXPERIENCE OF USE IN FOREIGN PRACTICE. LITERATURE REVIEW.

  2024cites this paper
• Single Versus Double Dose Tamsulosin for Patients with Moderate or Severe Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia: Prospective Randomized Study

  2024cites this paper
• Changes of resistance indices after medication in benign prostatic hyperplasia: a prospective study

  2023cites this paper
• Alpha_1-adrenergic blockers selectively antagonize the contractions induced by 6-nitrodopamine in the human vas deferens

  2023cites this paper
• Effects of CYP2D6 allelic variants on therapy with tamsulosin in patients with benign prostatic hyperplasia

  2023cites this paper
• Benign prostatic hyperplasia

  2022cites this paper
• Therapeutic effect of acupuncture and moxa combustion on prostate hyperplasia

  2022cites this paper
• Loss of the Sympathetic Signal Produces Sterile Inflammation of the Prostate

  2022cites this paper
• Do weather parameters affect emergency room visits due to acute urinary retention?

  2021cites this paper
• Efficacy and tolerability of doxazosin gastro-intestinal therapeutic system versus tamsulosin in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia

  2021cites this paper
• Lenalidomide and pomalidomide inhibit growth of prostate stromal cells and human prostate smooth muscle contraction.

  2021cites this paper
• The efficacy and safety of silodosin-a review of literature

  2021cites this paper
• Introduction to benign prostatic hyperplasia

  2021cites this paper
• Seasonal Variation of Drug Prescription Rate for Overactive Bladder in Men Based on National Health Insurance Claims Data, 2012–2016

  2020cites this paper
• Linear pharmacokinetics of doxazosin in healthy subjects

  2020cites this paper
• Seasonal variations in overactive bladder drug prescription rates in women: a nationwide population-based study

  2020cites this paper
• Otorhinolaryngological adverse effects of urological drugs

  2020cites this paper
• Day Temperature Difference and Aggravation of Low Urinary Tract Symptom in Benign Prostate Hypertrophy Patients in Korea: a National Health Insurance Service-National Cohort-based study.

  2020cites this paper
• Treatment of Voiding LUTS

  2019cites this paper
• Akuter Harnverhalt bei Männern: Die Wirksamkeit von Alpha-Blockern beim Katheterauslassversuch nach Harnverhalt

  2019cites this paper
• Emerging drugs to target lower urinary tract symptomatology (LUTS)/benign prostatic hyperplasia (BPH): focus on the prostate

  2019cites this paper
• The Prostate and Benign Prostatic Hyperplasia

  2019cites this paper
• Inhibitory effect of α1D/1A antagonist 2-(1H-indol-3-yl)-N-[3-(4-(2-methoxyphenyl) piperazinyl) propyl] acetamide on estrogen/androgen-induced rat benign prostatic hyperplasia model in vivo.

  2019cites this paper
• Herbal medicine for benign prostatic hyperplasia

  2019cites this paper
• Seasonal Variation of Overactive Bladder Symptoms in Female Patients

  2019cites this paper
• Revisiting the Pharmacodynamic Uroselectivity of α1-Adrenergic Receptor Antagonists

  2019cites this paper
• Comparison of the Effect of Naftopidil 75 mg and Tamsulosin 0.2 mg on the Bladder Storage Symptom With Benign Prostatic Hyperplasia: Prospective, Multi-institutional Study.

  2018cites this paper
• Inhibition of smooth muscle contraction and ARF6 activity by the inhibitor for cytohesin GEFs, secinH3, in the human prostate.

  2018cites this paper
• An efficient spectrofluorimetric method adopts doxazosin, terazosin and alfuzosin coupling with orthophthalaldehyde: Application in human plasma.

  2018cites this paper
• Effect of Climatic Parameters on Acute Urinary Retention Incidence

  2018cites this paper
• Effects of CYP2D6 and CYP3A5 genetic polymorphisms on steady-state pharmacokinetics and hemodynamic effects of tamsulosin in humans

  2018cites this paper
• Is Tamsulosin Linked to Dementia in the Elderly?

  2018cites this paper
• Best Prophylactic Strategy in Groups at Risk of Intraoperative Floppy Iris Syndrome Development: Comparison Between Atropine Instillation and Adrenaline Intracameral Injection

  2018cites this paper
• Non‐Adrenergic, Tamsulosin‐Insensitive Smooth Muscle Contraction is Sufficient to Replace α1‐Adrenergic Tension in the Human Prostate

  2017cites this paper
• Benign prostatic hyperplasia: Evaluation and medical management in primary care

  2017cites this paper
• Changes in autonomic nervous system activity after treatment with alpha-blocker in men with lower urinary tract symptoms

  2017cites this paper
• A Study on Efficacy and Safety of Silodosin in Geriatric Patients with Benign Prostatic Hyperplasia

  2017cites this paper
• Identification of 3,4-dihydro-2H-thiochromene 1,1-dioxide derivatives with a phenoxyethylamine group as highly potent and selective α1D adrenoceptor antagonists.

  2017cites this paper
• Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia, and Urinary Retention.

  2017cites this paper
• Additive naftopidil treatment synergizes docetaxel-induced apoptosis in human prostate cancer cells

  2017cites this paper
• Saw Palmetto for Symptom Management During Radiation Therapy for Prostate Cancer.

  2016cites this paper
• Re: The Effect of Competing Direct-to-Consumer Advertising Campaigns on the Use of Drugs for Benign Prostatic Hyperplasia: Time Series Analysis.

  2016cites this paper
• Design, Synthesis, and Biological Evaluation of Indoline and Indole Derivatives as Potent and Selective α1A-Adrenoceptor Antagonists.

  2016cites this paper
• Management of Benign Prostatic Hyperplasia.

  2016cites this paper
• Highly Sensitive Fluorescence Methods for the Determination of Alfuzosin, Doxazosin, Terazosin and Prazosin in Pharmaceutical Formulations, Plasma and Urine

  2016cites this paper
• Benign Prostatic Hyperplasia and LUTS

  2016cites this paper
• Effect of Selective Prostaglandin E2 EP2 Receptor Agonist CP‐533,536 on Voiding Efficiency in Rats with Midodrine‐Induced Functional Urethral Obstruction

  2016cites this paper
• Design, Synthesis, and Biological Evaluation of Novel Tetrahydroprotoberberine Derivatives (THPBs) as Selective α1A-Adrenoceptor Antagonists.

  2016cites this paper
• Doxazosin oral intake therapy to relieve stent - related urinary symptoms and pain: a prospective, randomized, controlled study

  2016cites this paper
• Highly sensitive spectrofluorimetric method for determination of doxazosin through derivatization with fluorescamine; Application to content uniformity testing.

  2016cites this paper
• Effect of 5α-Reductase Inhibitors on Sexual Function: A Meta-Analysis and Systematic Review of Randomized Controlled Trials.

  2016cites this paper
• Biased α-adrenergic receptor and βarrestin signaling in a cell culture model of benign prostatic hyperplasia.

  2016cites this paper
• Design , Synthesis , and Biological Evaluation of Novel Tetrahydroprotoberberine Derivatives ( THPBs ) as Selective α 1 A-Adrenoceptor Antagonists

  2016cites this paper
• Novel naftopidil-related derivatives and their biological effects as alpha1-adrenoceptors antagonists and antiproliferative agents.

  2015cites this paper
• Alfuzosin Treatment Improves The Rate and Time for Stone Expulsion in Patients with Distal Uretral Stones: A Prospective Randomized Controlled Study

  2015cites this paper
• Alpha-Blocker Treatment Response in Men With Lower Urinary Tract Symptoms Based on Sympathetic Activity: Prospective, Multicenter, Open-Labeled, Observational Study

  2015cites this paper
• The effects of silodosin in the treatment of ureteral stent related symptoms

  2015cites this paper
• Seasonal Variation of Urinary Symptoms in Korean Men with Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia

  2015cites this paper
• Upregulation of Phosphodiesterase type 5 in the Hyperplastic Prostate

  2015cites this paper
• Differential Response to Medical Therapy for Male Lower Urinary Tract Symptoms

  2015cites this paper
• The Effect of Competing Direct-to-Consumer Advertising Campaigns on the Use of Drugs for Benign Prostatic Hyperplasia: Time Series Analysis

  2015cites this paper
• Effects of Silodosin on Lower Urinary Tract Symptoms Due to a Double-J Stent: A Prospective Randomized Study

  2015cites this paper
• The supplement-drug interaction of quercetin with tamsulosin on vasorelaxation.

  2015cites this paper
• Identification of a new pharmacological activity of the phenylpiperazine derivative naftopidil: tubulin-binding drug

  2015cites this paper
• A comparison of the efficacy of naftopidil and tamsulosin hydrochloride in medical treatment of benign prostatic enlargement

  2015cites this paper
• Assessment of Tamsulosin 0.2 mg for Symptomatic Bladder Outlet Obstruction Secondary to Benign Prostatic Enlargement: Data from a Korean Multicenter Cross-Sectional Study

  2015cites this paper
• Validated HPTLC method for the simultaneous determination of alfuzosin, terazosin, prazosin, doxazosin and finasteride in pharmaceutical formulations

  2014cites this paper
• Editorial Comment to Cyclic guanosine monophosphate‐enhancing reduces androgenic extracellular regulated protein kinases‐phosphorylation/Rho kinase II‐activation in benign prostate hyperplasia

  2014cites this paper
• Effects of Schisandra chinensis extract on the relaxation of isolated human prostate tissue and smooth muscle cell.

  2014cites this paper
• α‐Adrenergic Antagonists for Lower Urinary Symptoms Secondary to Benign Prostatic Hyperplasia

  2014cites this paper
• Inhibition of smooth muscle force generation by focal adhesion kinase inhibitors in the hyperplastic human prostate.

  2014influential citation
• Filename Chapter 6: Tamsulosin - modified release and oral controlled absorption system formulations in the treatment of benign prostatic hyperplasia Version unknown

  2014cites this paper
• Structure-affinity/activity relationships of 1,4-dioxa-spiro[4.5]decane based ligands at α1 and 5-HT1A receptors.

  2014cites this paper
• Determination of Doxazosin Enantiomers in Human Plasma by Liquid Chromatography Tandem Mass Spectrometry using a Polysaccharide based Chiral Stationary Phase

  2014cites this paper
• Prostatic α1‐adrenoceptors: New concepts of function, regulation, and intracellular signaling

  2014cites this paper
• Fluorine in pharmaceutical industry: fluorine-containing drugs introduced to the market in the last decade (2001-2011).

  2014cites this paper
• Combination Medical Therapy for Male Lower Urinary Tract Symptoms

  2014cites this paper
• Drug-Related Problems in Patients with Benign Prostatic Hyperplasia: A Cross Sectional Retrospective Study

  2014cites this paper
• A Survey of the FAERS Database Concerning the Adverse Event Profiles of α1-Adrenoreceptor Blockers for Lower Urinary Tract Symptoms

  2013cites this paper
• The cAMP effector EPAC activates Elk1 transcription factor in prostate smooth muscle, and is a minor regulator of α1-adrenergic contraction

  2013cites this paper
• Structure-activity relationships in 1,4-benzodioxan-related compounds. 11. (1) reversed enantioselectivity of 1,4-dioxane derivatives in α1-adrenergic and 5-HT1A receptor binding sites recognition.

  2013cites this paper
• The receptor antagonist picotamide inhibits adrenergic and thromboxane-induced contraction of hyperplastic human prostate smooth muscle.

  2013cites this paper
• Gold(I)-catalyzed cascade approach for the synthesis of tryptamine-based polycyclic privileged scaffolds as α1-adrenergic receptor antagonists.

  2013cites this paper
• Intraoperative Floppy-Iris Syndrome: Comparison of Tamsulosin and Drugs Other Than Alpha Antagonists

  2013cites this paper
• The effect of first dose of tamsulosin on flow rate and its predictive ability on the improvement of LUTS in men with BPH in the mid-term

  2013cites this paper
• Intraoperative floppy iris syndrome (IFIS) in patients receiving tamsulosin or doxazosin—a UK-based comparison of incidence and complication rates

  2013cites this paper
• Noradrenaline induces binding of Clathrin light chain A to α1‐adrenoceptors in the human prostate

  2013cites this paper
• Ejaculation profiles of men following radiation therapy for prostate cancer.

  2013cites this paper
• Re: Tadalafil enhances the inhibitory effects of tamsulosin on neurogenic contractions of human prostate and bladder neck.

  2013cites this paper
• RETRACTED ARTICLE: Interaction Study Between Finasteride and Tamsulosin in Healthy Young Male Subjects

  2013cites this paper
• Effects of Doxazosin on Alpha 1‐Adrenergic Receptors in Prostates with Benign Prostatic Hyperplasia

  2013cites this paper